Aug 28, 2013 by Sherrie StoneWhy Wall Street Has Turned Against DendreonRecent calls on Dendreon might appear to be a joke, but given the company's outlook analysts may be correct.
Aug 22, 2013 by Sherrie StoneWill This Large Biotech Pop Experience Analyst Backlash?MannKind rose and fell significantly after announcing phase 3 data, as analysts questioned the report itself, but might Incyte experience a similar fate?
